세계의 전임상 이미징 시장 규모, 점유율, 동향 분석 : 제품별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Preclinical Imaging Market Growth & Trends:

The global preclinical imaging market size is estimated to reach USD 5.96 billion by 2030, registering to grow at a CAGR of 4.36% from 2025 to 2030 according to a new report by Grand View Research, Inc. Heavy investments in research and development are encouraging research projects worldwide. As a result, the demand for preclinical imaging is steadily increasing. Pharmaceuticals, biotechnology, life sciences, medical devices, and cosmetics are wide application areas, where imaging modalities are widely used in research and development. Furthermore, veterinary hospitals and educational institutions also create an additional demand for this market.

Nuclear medicine techniques (primarily, positron emission tomography (PET) and single photon emission computed tomography (SPECT)), optical imaging, micro-computed tomography (CT), micro magnetic resonance imaging (MRI), Photoacoustic tomography (PAT), and ultrasound are the most suitable modalities for small-animal in vivo imaging applications. Each modality has its own set of benefits and drawbacks. The multimodality devices designed to give complementary information on the pathophysiological process under research have rapidly gained popularity, seeking to overcome the inherent limits of each imaging modality. The combination of high-resolution modalities such as micro-CT and micro-MRI with highly sensitive techniques that provide functional information like micro-PET or micro-SPECT is expected to broaden the horizons of research in key areas like infection, oncology, cardiology, and neurology, contributing not only to the understanding of disease underlying mechanisms but also providing efficient and unique tools for evaluating new chemical entities and candidate drugs, thus boosting the global market growth.

The global market's prominent competitors are undertaking different initiatives for enhancing their product portfolio with novel product launches and enhancing their manufacturing capacity. For instance, In February 2023, at the 75th National Conference of the Indian Radiological and Imaging Association, FUJIFILM India announced the development of its equipment and service offerings. The company demonstrated cutting-edge diagnostic tools at the event in Amritsar from February 2-5, 2023. The recently released MRI machine APERTO Lucent Non DICOM printer APEOS and the ultrasound devices Arietta 650 DeepInsight and Arietta 850 DeepInsight are all components of the new portfolio. A smartphone application for assistance and guidance called "FUJIFILM Connect" was additionally released by the company.

Moreover, the advancements in the high-throughput ultrasound imaging system used in the application of cancer research and studies boost the market. In April 2022, the Vega imaging system, a handheld ultrasound system with fully automated technology and high-throughput capacity, which can speed up non-invasive clinical research and drug discovery in the fields of cancer, kidney and liver disease, and heart disease, was launched by PerkinElmer as an aspect of the company's announcement of a broadening of its live image analysis. The use of non-invasive imaging methods is encouraged since they reduce the need for invasive operations while minimizing animals' discomfort to a minimum. Preclinical imaging techniques have been adopted as a result of this ethical consideration.

Preclinical Imaging Market Report Highlights:

• The optical imaging segment held the largest revenue share of 13.6% in 2024 owing to their wide usage in small animal imaging and new drug discovery projects.
• In terms of application, the research & development segment captured the largest revenue share in 2024.
• The pharma and biotech companies segment captured the largest revenue share of 39.9% in 2024. The demand for pre-clinical imaging in biotech companies has been steadily increasing in recent years and is expected to continue growing in the coming years.
• North America preclinical imaging market held the largest revenue share of 30.1% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. End use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Preclinical Imaging Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Technological advancements
    • 3.2.1.2. Growing number of investments and funding in research and development
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Strict regulatory framework
• 3.3. Preclinical Imaging Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Preclinical Imaging Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Preclinical Imaging Product Market Movement Analysis
• 4.3. Global Preclinical Imaging Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
• 4.4. CT
  • 4.4.1. CT market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. MRI
  • 4.5.1. MRI market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. PET/SPECT
  • 4.6.1. PET/SPECT market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Multi Modal
  • 4.7.1. Multi modal market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Optical
  • 4.8.1. Optical market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Ultrasound
  • 4.9.1. Ultrasound market estimates and forecasts 2018 to 2030 (USD Million)
• 4.10. Photoacoustic
  • 4.10.1. Photoacoustic market estimates and forecasts 2018 to 2030 (USD Million)
• 4.11. Reagents
  • 4.11.1. Reagents market estimates and forecasts 2018 to 2030 (USD Million)
• 4.12. Services
  • 4.12.1. Services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Preclinical Imaging Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Preclinical Imaging Application Market Movement Analysis
• 5.3. Global Preclinical Imaging Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 5.4. Research and Development
  • 5.4.1. Research and development market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Drug Discovery
  • 5.5.1. Drug discovery market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Preclinical Imaging Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Global Preclinical Imaging End Use Market Movement Analysis
• 6.3. Global Preclinical Imaging Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Pharma and Biotech Companies
  • 6.4.1. Pharma and biotech companies market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Research Institutes
  • 6.5.1. Research institutes market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Preclinical Imaging Market: Regional Estimates & Trend Analysis By Product, Application, End Use

• 7.1. Regional Market Share Analysis, 2025 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Competitive scenario
    • 7.5.1.3. Regulatory framework
    • 7.5.1.4. Reimbursement structure
    • 7.5.1.5. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Competitive scenario
    • 7.5.2.3. Regulatory framework
    • 7.5.2.4. Reimbursement structure
    • 7.5.2.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. Mexico
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Competitive scenario
    • 7.5.3.3. Regulatory framework
    • 7.5.3.4. Reimbursement structure
    • 7.5.3.5. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Competitive scenario
    • 7.6.1.3. Regulatory framework
    • 7.6.1.4. Reimbursement structure
    • 7.6.1.5. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement structure
    • 7.6.2.5. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement structure
    • 7.6.3.5. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement structure
    • 7.6.4.5. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Competitive scenario
    • 7.6.5.3. Regulatory framework
    • 7.6.5.4. Reimbursement structure
    • 7.6.5.5. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Competitive scenario
    • 7.6.6.3. Regulatory framework
    • 7.6.6.4. Reimbursement structure
    • 7.6.6.5. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Competitive scenario
    • 7.6.7.3. Regulatory framework
    • 7.6.7.4. Reimbursement structure
    • 7.6.7.5. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Competitive scenario
    • 7.6.8.3. Regulatory framework
    • 7.6.8.4. Reimbursement structure
    • 7.6.8.5. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement structure
    • 7.7.1.5. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement structure
    • 7.7.2.5. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement structure
    • 7.7.3.5. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement structure
    • 7.7.4.5. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement structure
    • 7.7.5.5. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement structure
    • 7.7.6.5. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement structure
    • 7.8.1.5. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Argentina
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement structure
    • 7.8.2.5. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement structure
    • 7.9.1.5. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement structure
    • 7.9.2.5. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Competitive scenario
    • 7.9.3.3. Regulatory framework
    • 7.9.3.4. Reimbursement structure
    • 7.9.3.5. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Competitive scenario
    • 7.9.4.3. Regulatory framework
    • 7.9.4.4. Reimbursement structure
    • 7.9.4.5. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Key company market share analysis, 2025
• 8.4. Company Position Analysis
• 8.5. Company Categorization (Emerging Players, Innovators and Leaders)
• 8.6. Company Profiles
  • 8.6.1. Bruker Corporation
    • 8.6.1.1. Company overview
    • 8.6.1.2. Financial performance
    • 8.6.1.3. Product benchmarking
    • 8.6.1.4. Strategic initiatives
  • 8.6.2. Siemens A.G.
    • 8.6.2.1. Company overview
    • 8.6.2.2. Financial performance
    • 8.6.2.3. Product benchmarking
    • 8.6.2.4. Strategic initiatives
  • 8.6.3. General Electric (GE)
    • 8.6.3.1. Company overview
    • 8.6.3.2. Financial performance
    • 8.6.3.3. Product benchmarking
    • 8.6.3.4. Strategic initiatives
  • 8.6.4. TriFoil Imaging
    • 8.6.4.1. Company overview
    • 8.6.4.2. Financial performance
    • 8.6.4.3. Product benchmarking
    • 8.6.4.4. Strategic initiatives
  • 8.6.5. PerkinElmer, Inc.
    • 8.6.5.1. Company overview
    • 8.6.5.2. Financial performance
    • 8.6.5.3. Product benchmarking
    • 8.6.5.4. Strategic initiatives
  • 8.6.6. VisualSonics Inc. (Fujifilm)
    • 8.6.6.1. Company overview
    • 8.6.6.2. Financial performance
    • 8.6.6.3. Product benchmarking
    • 8.6.6.4. Strategic initiatives
  • 8.6.7. Mediso Ltd.
    • 8.6.7.1. Company overview
    • 8.6.7.2. Financial performance
    • 8.6.7.3. Product benchmarking
    • 8.6.7.4. Strategic initiatives
  • 8.6.8. Agilent Technologies
    • 8.6.8.1. Company overview
    • 8.6.8.2. Financial performance
    • 8.6.8.3. Product benchmarking
    • 8.6.8.4. Strategic initiatives
  • 8.6.9. MILabs B.V.
    • 8.6.9.1. Company overview
    • 8.6.9.2. Financial performance
    • 8.6.9.3. Product benchmarking
    • 8.6.9.4. Strategic initiatives
  • 8.6.10. MR Solutions
    • 8.6.10.1. Company overview
    • 8.6.10.2. Financial performance
    • 8.6.10.3. Product benchmarking
    • 8.6.10.4. Strategic initiatives
  • 8.6.11. Molecubes
    • 8.6.11.1. Company overview
    • 8.6.11.2. Financial performance
    • 8.6.11.3. Product benchmarking
    • 8.6.11.4. Strategic initiatives